Literature DB >> 29038277

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

George L Drusano1, Michael L Corrado2, Gino Girardi3, Evelyn J Ellis-Grosse4, Richard G Wunderink5, Helen Donnelly5, Kenneth V Leeper6, Mona Brown6, Tasnova Malek6, Robert Duncan Hite7, Michelle Ferrari7, Danijela Djureinovic7, Marin H Kollef8, Lisa Mayfield8, Ann Doyle8, Jean Chastre9, Alain Combes9, Thomas J Walsh10, Krisztina Dorizas10, Hassan Alnuaimat11, Brooks Edward Morgan11, Jordi Rello12, Cristopher A Mazo12, Ronald N Jones13, Robert K Flamm13, Leah Woosley13, Paul G Ambrose14, Sujata Bhavnani14, Christopher M Rubino14, Catharine C Bulik14, Arnold Louie15, Michael Vicchiarelli15, Colleen Berman15.   

Abstract

Ventilator-associated bacterial pneumonia (VABP) is a difficult therapeutic problem. Considerable controversy exists regarding the optimal chemotherapy for this entity. The recent guidelines of the Infectious Diseases Society of America and the American Thoracic Society recommend a 7-day therapeutic course for VABP based on the balance of no negative impact on all-cause mortality, less resistance emergence, and fewer antibiotic treatment days, counterbalanced with a higher relapse rate for patients whose pathogen is a nonfermenter. The bacterial burden causing an infection has a substantial impact on treatment outcome and resistance selection. We describe the baseline bronchoalveolar lavage (BAL) fluid burden of organisms in suspected VABP patients screened for inclusion in a clinical trial. We measured the urea concentrations in plasma and BAL fluid to provide an index of the dilution of the bacterial and drug concentrations in the lung epithelial lining fluid introduced by the BAL procedure. We were then able to calculate the true bacterial burden as the diluted colony count times the dilution factor. The median dilution factor was 28.7, with the interquartile range (IQR) being 11.9 to 53.2. Median dilution factor-corrected colony counts were 6.18 log10(CFU/ml) [IQR, 5.43 to 6.46 log10(CFU/ml)]. In a subset of patients, repeat BAL on day 5 showed a good stability of the dilution factor. We previously showed that large bacterial burdens reduce or stop bacterial killing by granulocytes. (This study has been registered at ClinicalTrials.gov under registration no. NCT01570192.).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  bacterial burden; bronchoalveolar lavage; ventilator-associated bacterial pneumonia

Mesh:

Substances:

Year:  2017        PMID: 29038277      PMCID: PMC5740323          DOI: 10.1128/AAC.01323-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 2.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Authors:  G L Drusano; William Hope; Alasdair MacGowan; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

Authors:  George Louis Drusano; Weiguo Liu; Steven Fikes; Ryan Cirz; Nichole Robbins; Stephanie Kurhanewicz; Jaime Rodriquez; David Brown; Dodge Baluya; Arnold Louie
Journal:  J Infect Dis       Date:  2014-04-22       Impact factor: 5.226

4.  The value of routine microbial investigation in ventilator-associated pneumonia.

Authors:  J Rello; M Gallego; D Mariscal; R Soñora; J Valles
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

5.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

6.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

7.  Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.

Authors:  G L Drusano; B Vanscoy; W Liu; S Fikes; D Brown; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

8.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

9.  Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group.

Authors:  F Alvarez-Lerma
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

10.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Authors:  Jean Chastre; Michel Wolff; Jean-Yves Fagon; Sylvie Chevret; Franck Thomas; Delphine Wermert; Eva Clementi; Jesus Gonzalez; Dominique Jusserand; Pierre Asfar; Dominique Perrin; Fabienne Fieux; Sylvie Aubas
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

  10 in total
  6 in total

1.  Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Safa S Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Authors:  Cornelia B Landersdorfer; Rajbharan Yadav; Jürgen B Bulitta; Kate E Rogers; Tae Hwan Kim; Beom Soo Shin; John D Boyce; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings.

Authors:  Iris K Minichmayr; Suzanne Kappetein; Margreke J E Brill; Lena E Friberg
Journal:  Antibiotics (Basel)       Date:  2022-08-01

Review 5.  Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Authors:  Rakel Arrazuria; Bernhard Kerscher; Karen E Huber; Jennifer L Hoover; Carina Vingsbo Lundberg; Jon Ulf Hansen; Sylvie Sordello; Stephane Renard; Vincent Aranzana-Climent; Diarmaid Hughes; Philip Gribbon; Lena E Friberg; Isabelle Bekeredjian-Ding
Journal:  Front Microbiol       Date:  2022-09-08       Impact factor: 6.064

6.  Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.

Authors:  Michael Maynard; G L Drusano; Michael Vicchiarelli; Weiguo Liu; Jenny Myrick; Jocelyn Nole; Brandon Duncanson; David Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.